Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. - Wikidata - awgldk - TriplyDB

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

http://www.wikidata.org/entity/Q30009098

about

Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site Emerging Therapies for Rheumatoid Arthritis Clinical Pharmacology and Translational Aspects of Bispecific Antibodies Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.Targeting the interleukin-23/17 axis in axial spondyloarthritis.Targeting IL-17 in autoimmunity and inflammation.A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.In vitro-engineered non-antibody protein therapeutics.Affibody molecules as engineered protein drugs.The Plasticity of Th17 Cells in the Pathogenesis of Rheumatoid Arthritis A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.Current progress in innovative engineered antibodies.VHH-Based Bispecific Antibodies Targeting Cytokine Production The making of bispecific antibodies A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A.Targeting IL-17 in psoriatic arthritis.Bispecific antibodies: design, therapy, perspectives.What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?A revolutionary therapeutic approach for psoriasis: bispecific biological agents.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Recent advances in ankylosing spondylitis: understanding the disease and management

P2860

Q28066935-90487624-B8E9-4CC2-B999-F3F70E18100B Q28078943-31D92FDB-DD6A-424D-BD43-36EE62765474 Q33648086-301F8FB9-2466-43D4-8F59-9F52E0D956BE Q36333938-DA5D8C8B-3C2B-4DE0-88DC-D9070876C04A Q38827500-4A8E00C7-2BD9-45A7-9B5F-6260FEF2E19C Q38941407-F9708F1F-6589-4421-86E7-EC122878CD08 Q38968548-35BC0E62-467C-40BA-BAF2-3343412BA05F Q39167522-1F66D911-9DDE-4819-999B-F9CB8032DAB3 Q39197528-DC797CCF-0B9D-49CC-84C0-F44D42B72793 Q39429529-5A58DAAB-3D8F-4189-B6D5-50915D07CE09 Q40066330-F5165388-7E82-471F-B480-30E95FDEE11E Q40077818-DBBCE220-D88A-4833-80E4-12C88EFBF41D Q41619629-35748D5F-CE9E-45F2-85D4-B23FAE2EBC02 Q42323236-CDDF5B56-AD3D-4083-BB47-40AA0F271BB7 Q47102100-47E96093-A484-4521-97B3-5C2D61F4135F Q47140713-074830DF-C45A-4342-842E-B7EDF9A80623 Q49195146-122FF39C-612F-4F67-971F-10EA89D3B2A2 Q50081141-856A635B-3F77-4956-871D-182B2DDC9B48 Q54422386-01A33715-5D42-440C-A2D1-3E71147B8FD7 Q55052878-73CD39B1-03AB-4DDE-9FAE-790578862AC5 Q57821877-45E9FBF5-E52E-4234-8884-625468209B8A

P2860

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

http://www.wikidata.org/entity/Q30009098

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Discovery and characterization ...... ment of inflammatory diseases.

@ast

Discovery and characterization ...... ment of inflammatory diseases.

@en

type

label

Discovery and characterization ...... ment of inflammatory diseases.

@ast

Discovery and characterization ...... ment of inflammatory diseases.

@en

prefLabel

Discovery and characterization ...... ment of inflammatory diseases.

@ast

Discovery and characterization ...... ment of inflammatory diseases.

@en

P1433

Q30009098-D3BB0CDB-91A8-41E2-8C9B-6F473699084A

P1476

Q30009098-493B5FAC-997F-4B3D-8646-84C7EE26978D

P2093

Q30009098-19A18BC2-899D-4BFE-AF4C-1D1E0D6D4B43

Q30009098-3FD0166D-B81E-412F-9847-EC13A08E28A1

Q30009098-46B7827C-E00B-4856-8411-AA2AC35FD0D3

Q30009098-50FBD0E2-4B54-4DC8-AD2E-7C8C4B40BC58

Q30009098-599EB733-F8CF-42FC-B6F3-94E9982DC6C7

Q30009098-5D6ED4C5-B43B-4AB9-8FA8-2820FBB68556

Q30009098-6C6A8D93-349B-472F-AE18-6F172582D1CC

Q30009098-764B429E-02AF-49EC-85E3-E1A2B82685CE

Q30009098-9AB1E593-EA5D-4207-8C98-075B89469E40

Q30009098-A3848E67-A50D-4165-B14D-D8421FBB1710

P2860

Q30009098-0A0790E4-E876-4E9A-8832-BFBB6DD8AE58

Q30009098-0D0D4460-F80F-4A06-B8CA-B69FA3EEDFA9

Q30009098-121963DB-6BB4-4792-917F-0917449A000E

Q30009098-1BFC5D3B-D71D-4E70-9462-1D1F5965D0D0

Q30009098-2A3CFE3D-002D-4BB7-B0ED-106D6FF9BDB3

Q30009098-3E59A13C-3C5C-4D2E-9863-FB7041D96BBD

Q30009098-433FEC4E-24B7-4497-B0CE-2BFC69C45837

Q30009098-4A6772FE-3190-41FC-9A75-5C026F27D9F0

Q30009098-4B0EE7B5-4CFE-449C-B696-C39681877A0C

Q30009098-66FAE17E-DD8F-4406-B547-515BAF586B13

P304

Q30009098-F2BDA2EC-D869-4432-A6CC-6922015759C8

P31

Q30009098-2B00B9E0-3DF1-4672-B9F1-2BA1F90854DE

P3181

Q30009098-A590F80D-E214-4354-87FB-B342C0718F0F

P356

Q30009098-73AD482E-66F7-469C-897B-44A9E1539F31

P433

Q30009098-16A6E0CC-DA33-4411-A57D-BC9861181F4A

P478

Q30009098-43A5919F-0CA7-40BE-88AB-77FAE0863554

P577

Q30009098-31DC567D-7176-4180-912E-0F678FD6A17D

P698

Q30009098-A02CF0A5-2D93-4D6E-B4C7-9E7FF4A88409

P932

Q30009098-AAD1AEA5-2490-469F-81CE-61969FC29DF1

P3181

P356

19420862.2015.1093266

P1433

Monoclonal Antibodies

P1476

Discovery and characterization ...... ment of inflammatory diseases.

@en

P2093

Bernd Schlereth

http://www.w3.org/2001/XMLSchema#string

Dragan Grabulovski

http://www.w3.org/2001/XMLSchema#string

Isabella Attinger-Toller

http://www.w3.org/2001/XMLSchema#string

Julian Bertschinger

http://www.w3.org/2001/XMLSchema#string

Mathias Locher

http://www.w3.org/2001/XMLSchema#string

Michela Silacci

http://www.w3.org/2001/XMLSchema#string

Nadja Baenziger-Tobler

http://www.w3.org/2001/XMLSchema#string

Richard Woods

http://www.w3.org/2001/XMLSchema#string

Roger Santimaria

http://www.w3.org/2001/XMLSchema#string

Sarah Batey

http://www.w3.org/2001/XMLSchema#string

P2860

A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis

Structure of IL-17A in complex with a potent, fully human neutralizing antibody

Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain

Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones

Bispecific antibodies for cancer immunotherapy: Current perspectives

A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action.

Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency.

Selection of single domain binding proteins by covalent DNA display.

P304

141-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4795912

http://www.w3.org/2001/XMLSchema#string

P356

10.1080/19420862.2015.1093266

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26390837

http://www.w3.org/2001/XMLSchema#string

P932

4966518

http://www.w3.org/2001/XMLSchema#string